Echinococcus Granulosus IgG ELISA

$396.00
Catalog
20-EGGHU-E01

The Echinococcus IgG ELISA is for the qualitative and semi-quantitative determination of IgG-class antibodies to Echinococcus in human serum and (EDTA-, heparin-, or citrate-) plasma. For in vitro diagnostic use in the United States.  For Research Use Only outside of the United States.

 

Echinococci are microscopic cestodes (tapeworms) ranging in length from 1.4 to 6 mm, dependent on their genus. They are found:

  • In dogs or other canids (E. granulosus)
  • In foxes, coyotes, and wolves (E. multilocularis)

Sources of infection are final hosts (i.e., dogs for E. granulosus and mainly foxes for E. multilocularis) and food contaminated with parasite eggs. After ingestion of a suitable intermediate host, the egg hatches in the small bowel and releases an oncosphere that penetrates the intestinal wall and travels through the circulatory system into various organs where it develops into a cyst. Echinococcus infections remain silent for years before the enlarging cysts cause symptoms in the affected organs.

E. granulosus larvae (oncospheres) begin to vesiculate mainly in the liver but also in the lungs and other organs (20%). The parasites form spherical, unilocular, fluid-filled cysts and can achieve diameters between 1 cm and 15 cm. In contrast to cystic echinococcosis, E. multilocularis larvae are found almost exclusively (98%) in the liver, though secondary lesions can spread metastatically to other organs (lungs, kidneys, CNS, and others). The parasites grow infiltratively and tumor-like in the host tissue.

E. granulosus occurs worldwide, while E. multilocularis is found in the northern hemisphere, including central Europe and the northern parts of Europe, Asia, and North America.

Detectable immune responses have been associated with the location, integrity, and vitality of the larval cyst. Cysts in the liver are more likely to elicit an antibody response than cysts in the lungs. Regardless of localization, antibody detection tests are less sensitive in patients with intact hyaline cysts. Cysts in the lungs, brain, and spleen are associated with lowered serodiagnostic reactivity, whereas those in bone appear to more regularly stimulate detectable antibodies. Fissuration or rupture of a cyst is followed by an abrupt stimulation of antibodies.

Differentiation between both species of Echinococcus is not possible.

Species
Human
Regulatory Status
FDA Registered. For In Vitro Diagnostic Use.
Product Distribution
Available Worldwide
Range
pos./ neg. / cut off control
Sizes
96 Wells
Sample Types
Citrate Plasma, EDTA Plasma, Heparin Plasma, Serum
Inc Time Hour
1
Inc Time Minute
45
Inc Time Overnight
No
Inc Time See Protocol
No
Sample Size
10
Detection
Colorimetric

Echinococcus Granulosus IgG ELISA

20-EGGHU-E01

Billing Address

Shipping Address

Resources to advance your discoveries 

Recent posts

8 Questions to Ask Before Choosing an Allergy Testing Platform
8 Questions to Ask Before Choosing an Allergy Testing Platform
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
View Now
Understanding IgE Allergy Test Results
Understanding IgE Allergy Test Results
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
View Now
Improving Food Elimination Diets with IgG Testing
Improving Food Elimination Diets with IgG Testing
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
View Now

Recent posts

An End to Subjective RPR Reading?
An End to Subjective RPR Reading? Development of a Novel Automated Nontreponemal Immunoassay for Syphilis
Discover ALPCO’s novel automated nontreponemal immunoassay for syphilis testing. Reduce subjectivity, improve workflow efficiency, and support faster treatment decisions.
View Now
Variation In Calprotectin Results by Methodology
Same Sample, Different Result? What New Research Reveals About Fecal Calprotectin Variability
In a head-to-head comparison of FDA-cleared assays and a novel ALPCO method, investigators observed wide variability in specificity and false-positive rates across platforms, raising important questions about standardization and clinical interpretation.
View Now
ALPCO News
NuvinkaDx Announces Major Milestones for Portfolio Companies GeneProof and ALPCO
July 22, 2025 – Salem, NH – NuvinkaDx, a leading innovator in diagnostic solutions, today announced two significant product and regulatory milestones from its operating companies, GeneProof and ALPCO.
View Now

Biomarkers of Energy Homeostasis Brochure

Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.

Complement System Solutions for Drug Development and Clinical Research Datasheet

The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.

Melatonin Products for Sleep Disorder-Related Research Datasheet

The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.